FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1497903288> ?p ?o ?g. }

• W1497903288 endingPage "1268" @default.
• W1497903288 startingPage "1262" @default.
• W1497903288 abstract "Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? Pelvic lymph‐node dissection during radical prostatectomy for prostate cancer is certainly a fundamental staging procedure but its therapeutic role is yet under debate. This retrospective study suggests that, in patients with intermediate‐ and high‐risk of prostate cancer, the greater the number of lymph‐nodes removed, the lower the risk of biochemical relapse, even in the presence of 1 or 2 lymph‐node metastasis. However, the Will Rogers phenomenon must be considered due to the retrospective nature of the present study. OBJECTIVE To assess the impact of pelvic lymph node dissection (PLND) and of the number of lymph nodes (LNs) retrieved during radical prostatectomy (RP) on biochemical relapse (BCR) in pNX/0/1 patients with prostate cancer according to the clinical risk of lymph node invasion (LNI). PATIENTS AND METHODS We evaluated 872 pT2‐4 NX/0/1 consecutive patients submitted to RP between October 1995 and June 2009, with the following inclusion criteria: (i) a follow‐up period ≥12 months; (ii) the avoidance of neoadjuvant hormonal therapy or adjuvant hormonal and/or adjuvant radiotherapy; (iii) the availability of complete follow‐up data; (iv) no pathological T0 disease; (v) complete data regarding the clinical stage and Gleason score (Gs), the preoperative prostate‐specific antigen (PSA) level and the pathological stage. The patients were stratified as having low risk (cT1a‐T2a and cGs ≤6 and PSA level < 10 ng/mL), intermediate risk (cT2b‐T2c or cGs = 7 or PSA level = 10–19.9) or high risk of LNI (cT3 or cGs = 8–10 or PSA level ≥ 20). The 872 patients were divided into two LN groups according to the number of LNs retrieved: group 1 had no LN or one to nine LNs removed; group 2 had 10 or more LNs. The variables analysed were LN group, age, PSA level, clinical and pathological stage and Gs, surgical margin status, LN status and number of LN metastases; the primary endpoint was the BCR‐free survival. RESULTS The mean follow‐up was 55.8 months. Of all the patients, 305 (35%) were pNx and 567 (65.0%) were pN0/1. Of the 567 patients submitted to PLND, the mean number of LNs obtained was 10.9, and 49 (8.6%) were pN1. In the 402 patients at low risk of LNI, LN group was not a significant predictor of BCR at univariate analysis, while in the 470 patients at intermediate and high risk of LNI, patients with ≥10 LNs removed had a significantly lower BCR‐free survival at univariate and multivariate analysis. CONCLUSION In our study population, a more extensive PLND positively affects the BCR‐free survival regardless of the nodal status in intermediate‐ and high‐risk prostate cancer." @default.
• W1497903288 created "2016-06-24" @default.
• W1497903288 creator A5002218114 @default.
• W1497903288 creator A5005989484 @default.
• W1497903288 creator A5009832966 @default.
• W1497903288 creator A5009887316 @default.
• W1497903288 creator A5013749521 @default.
• W1497903288 creator A5021881282 @default.
• W1497903288 creator A5029088271 @default.
• W1497903288 creator A5063552641 @default.
• W1497903288 creator A5065342572 @default.
• W1497903288 creator A5080774729 @default.
• W1497903288 creator A5090801942 @default.
• W1497903288 date "2011-03-29" @default.
• W1497903288 modified "2023-10-17" @default.
• W1497903288 title "The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer" @default.
• W1497903288 cites W1521292045 @default.
• W1497903288 cites W1975388219 @default.
• W1497903288 cites W1975388728 @default.
• W1497903288 cites W1978128021 @default.
• W1497903288 cites W1981497922 @default.
• W1497903288 cites W1996080642 @default.
• W1497903288 cites W2004625759 @default.
• W1497903288 cites W2006065724 @default.
• W1497903288 cites W2007911038 @default.
• W1497903288 cites W2020571250 @default.
• W1497903288 cites W2028328714 @default.
• W1497903288 cites W2037073425 @default.
• W1497903288 cites W2039978974 @default.
• W1497903288 cites W2041881426 @default.
• W1497903288 cites W2045276333 @default.
• W1497903288 cites W2049190466 @default.
• W1497903288 cites W2075007329 @default.
• W1497903288 cites W2080487345 @default.
• W1497903288 cites W2137571400 @default.
• W1497903288 cites W2143210159 @default.
• W1497903288 cites W2147437793 @default.
• W1497903288 cites W2154909756 @default.
• W1497903288 cites W2158334167 @default.
• W1497903288 cites W2159366134 @default.
• W1497903288 cites W2160679358 @default.
• W1497903288 cites W2164508251 @default.
• W1497903288 cites W4239180165 @default.
• W1497903288 cites W4322701587 @default.
• W1497903288 doi "https://doi.org/10.1111/j.1464-410x.2010.10016.x" @default.
• W1497903288 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21446934" @default.
• W1497903288 hasPublicationYear "2011" @default.
• W1497903288 type Work @default.
• W1497903288 sameAs 1497903288 @default.
• W1497903288 citedByCount "51" @default.
• W1497903288 countsByYear W14979032882012 @default.
• W1497903288 countsByYear W14979032882013 @default.
• W1497903288 countsByYear W14979032882014 @default.
• W1497903288 countsByYear W14979032882015 @default.
• W1497903288 countsByYear W14979032882016 @default.
• W1497903288 countsByYear W14979032882017 @default.
• W1497903288 countsByYear W14979032882018 @default.
• W1497903288 countsByYear W14979032882019 @default.
• W1497903288 countsByYear W14979032882020 @default.
• W1497903288 countsByYear W14979032882021 @default.
• W1497903288 countsByYear W14979032882022 @default.
• W1497903288 countsByYear W14979032882023 @default.
• W1497903288 crossrefType "journal-article" @default.
• W1497903288 hasAuthorship W1497903288A5002218114 @default.
• W1497903288 hasAuthorship W1497903288A5005989484 @default.
• W1497903288 hasAuthorship W1497903288A5009832966 @default.
• W1497903288 hasAuthorship W1497903288A5009887316 @default.
• W1497903288 hasAuthorship W1497903288A5013749521 @default.
• W1497903288 hasAuthorship W1497903288A5021881282 @default.
• W1497903288 hasAuthorship W1497903288A5029088271 @default.
• W1497903288 hasAuthorship W1497903288A5063552641 @default.
• W1497903288 hasAuthorship W1497903288A5065342572 @default.
• W1497903288 hasAuthorship W1497903288A5080774729 @default.
• W1497903288 hasAuthorship W1497903288A5090801942 @default.
• W1497903288 hasConcept C121608353 @default.
• W1497903288 hasConcept C126322002 @default.
• W1497903288 hasConcept C126894567 @default.
• W1497903288 hasConcept C141071460 @default.
• W1497903288 hasConcept C142724271 @default.
• W1497903288 hasConcept C143998085 @default.
• W1497903288 hasConcept C146357865 @default.
• W1497903288 hasConcept C151730666 @default.
• W1497903288 hasConcept C167135981 @default.
• W1497903288 hasConcept C2775862295 @default.
• W1497903288 hasConcept C2776235491 @default.
• W1497903288 hasConcept C2777008409 @default.
• W1497903288 hasConcept C2778311097 @default.
• W1497903288 hasConcept C2779013556 @default.
• W1497903288 hasConcept C2779466945 @default.
• W1497903288 hasConcept C2779720271 @default.
• W1497903288 hasConcept C2780192828 @default.
• W1497903288 hasConcept C2780849966 @default.
• W1497903288 hasConcept C2781406297 @default.
• W1497903288 hasConcept C509974204 @default.
• W1497903288 hasConcept C71924100 @default.
• W1497903288 hasConcept C86803240 @default.
• W1497903288 hasConceptScore W1497903288C121608353 @default.
• W1497903288 hasConceptScore W1497903288C126322002 @default.

• next